港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,772.232

+40.7992.36%

漲家數：7

跌家數：- -

平家數：1

市盈率：- -

高：1,805.863

開：1,735.522

低：1,735.522

收：1,731.433

資料載入中...

總覽新聞資訊

宜明昂科-B(01541)獲國家藥監局批准進行替達派西普聯合珀維拉芙普α另加化療或不加化療用於治療晚期惡性腫瘤的臨牀試驗

第一三共/阿斯利康(AZN.US)重磅抗體偶聯藥物(ADC)Enhertu在3期臨牀試驗中獲得積極結果

石藥(01093.HK)：新藥JMT108獲批於中國開展臨牀試驗

阿斯达克财经

石藥集團(01093)開發的I類新藥雙功能融合蛋白藥物JMT108獲中國臨牀試驗批准

泰格醫藥03月05日主力淨流入624萬元散户資金拋售

昭衍新藥03月05日主力淨流入157萬元散户資金拋售

金斯瑞生物科技03月05日獲主力加倉250萬元

維亞生物03月05日主力淨流入3萬元散戶資金拋售

方達控股盤中異動大幅拉昇5.56%報1.140港元

港股異動 | 基石藥業-B(02616)漲超8% 治療實體瘤藥物臨牀試驗順利完成首例患者給藥

聯邦制藥現漲超4% 研發的UBT251注射液CKD適應症獲FDA批准新藥臨牀試驗

港股異動 | 聯邦制藥(03933)漲超5% 研發的UBT251注射液CKD適應症獲FDA批准新藥臨牀試驗

復星醫藥(02196.HK)24價肺炎球菌多糖結合疫苗於中國獲批臨牀試驗

阿斯达克财经

泰格醫藥(03347.HK)累計回購980.6萬股A股總金額5億人民幣

阿斯达克财经

泰格醫藥：累計回購公司股份9806300股

证券日报网

中證滬港深創新藥產業指數下跌0.57%，前十大權重包含藥明康德等

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1772.232,"timestamp":1741248510306,"preClose":1731.4331,"halted":0,"volume":100037287,"delay":0,"changeRate":0.023564,"change":40.79895,"pbRate":2.569388,"amount":2232823119,"amplitude":0.040626,"prevYearClose":1395.7731,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"turnoverRate":0.00862,"marketCap":380565866496,"floatMarketCap":164754930944,"peRate":32.042796},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1805.8632,"amplitude":0.040626,"preClose":1731.4331,"low":1735.5215,"pbRate":"2.569388","latestPrice":1772.232,"volume":100037287,"delay":0,"open":1735.5215,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"sixtyDayClose":1360.467,"secType":"PLATE","market":"HK","turnoverRate":0.00862,"peRate":32.042796,"marketCap":380565866496,"floatMarketCap":164754930944,"timestamp":1741248510306,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517392070","title":"宜明昂科-B(01541)獲國家藥監局批准進行替達派西普聯合珀維拉芙普α另加化療或不加化療用於治療晚期惡性腫瘤的臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517392070","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517392070?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 06:45","pubTimestamp":1741214752,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，集团已获中华人民共和国国家药品监督管理局批准进行IMM01联合IMM2510，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01及IMM2510的临床研究方面又迈出了关键一步。凭借差异化的分子设计，IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。集团拥有IMM01的全球知识产权及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1576","01541","BK1141","03347"],"gpt_icon":0},{"id":"2517111989","title":"第一三共/阿斯利康(AZN.US)重磅抗體偶聯藥物(ADC)Enhertu在3期臨牀試驗中獲得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2517111989","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517111989?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 21:15","pubTimestamp":1741180517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和第一三共公司日前宣布，双方联合开发的重磅抗体偶联药物Enhertu，在3期临床试验DESTINY-Gastric04中获得积极结果。新闻稿表示，Enhertu是首个在随机3期临床试验中，作为二线疗法显著改善HER2阳性胃癌患者总生存期的HER2靶向疗法。新闻稿指出，转移性HER2阳性胃癌一线治疗出现疾病进展后，历史上在随机临床试验中，尚未有HER2靶向药物在二线治疗中展示出生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU2456880835.USD","BK1576","BK4231","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","BK4588","ADC","BK4080","LU2462157665.USD","BK1583","BK1141","AZN","BK4568","BK4007","LU2236285917.USD","03347","LU0889565916.HKD","BK4585"],"gpt_icon":0},{"id":"2517996020","title":"石藥(01093.HK)：新藥JMT108獲批於中國開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517996020","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517996020?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:25","pubTimestamp":1741166700,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，由集团开发的一类新药双功能融合蛋白药物JMT108，已获国家药品监督管理局批准，可在中国开展临床试验。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，本次获批的临床适应症为晚期恶性肿瘤。集团表示，临床前研究显示该产品的适应症广泛，在多种恶性肿瘤模型中具有显著的抗肿瘤作用及良好的安全性，具有较高的临床开发价值。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422393/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0880133367.SGD","LU0140636845.USD","IE00B031HY20.USD","LU1226288170.HKD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0072913022.USD","BK1191","BK1141","IE00B543WZ88.USD","LU0326950275.SGD","BK1515","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287529.USD","SG9999004220.SGD","IE0008369823.USD","LU1226287792.SGD","LU0501845795.SGD","01093","IE00BZ08YT58.USD","03347","LU0067412154.USD","BK1583","LU1226287875.USD","LU1807302812.USD","BK1521","LU1226288253.USD","LU1008478684.HKD","BK1576","IE00B5MMRT66.SGD","IE0008368742.USD","LU1152091754.HKD"],"gpt_icon":0},{"id":"2517299674","title":"石藥集團(01093)開發的I類新藥雙功能融合蛋白藥物JMT108獲中國臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517299674","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517299674?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:22","pubTimestamp":1741166538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，该集团开发的I类新药双功能融合蛋白药物JMT108已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，通过靶向PD-1阳性肿瘤浸润免疫细胞，解除PD-1和PD-L1相互作用导致的免疫抑制，并通过PD-1抗体结合依赖性地激活IL-15下游信号通路，进一步促进相关免疫细胞的增殖和活化，从而达到增强的抗肿瘤疗效。本次获批的临床适应症为晚期恶性肿瘤。临床前研究显示，该产品的适应症广泛，在多种恶性肿瘤模型中具有显著的抗肿瘤作用及良好的安全性，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0880133367.SGD","LU0140636845.USD","IE00B031HY20.USD","LU1226288170.HKD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0072913022.USD","BK1191","BK1141","IE00B543WZ88.USD","LU0326950275.SGD","BK1515","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287529.USD","SG9999004220.SGD","IE0008369823.USD","LU1226287792.SGD","LU0501845795.SGD","01093","IE00BZ08YT58.USD","03347","LU0067412154.USD","BK1583","LU1226287875.USD","LU1807302812.USD","BK1521","LU1226288253.USD","LU1008478684.HKD","BK1576","IE00B5MMRT66.SGD","IE0008368742.USD","LU1152091754.HKD"],"gpt_icon":0},{"id":"2517995164","title":"泰格醫藥03月05日主力淨流入624萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517995164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517995164?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:16","pubTimestamp":1741162597,"startTime":"0","endTime":"0","summary":"03月05日, 泰格医药股价涨2.57%，报收33.95元，成交金额1.15亿元，换手率2.79%，振幅4.68%，量比0.78。泰格医药今日主力资金净流入624万元，上一交易日主力净流出345万元。该股近5个交易日下跌7.99%，主力资金累计净流出296万元；近20日主力资金累计净流入2033万元，其中净流入天数为9日。该股主力净额占比0.15%，港股市场排名61/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170437abe944b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170437abe944b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2517951749","title":"昭衍新藥03月05日主力淨流入157萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517951749","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517951749?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:16","pubTimestamp":1741162592,"startTime":"0","endTime":"0","summary":"03月05日, 昭衍新药股价涨3.10%，报收13.98元，成交金额2895万元，换手率1.75%，振幅5.16%，量比0.37。昭衍新药今日主力资金净流入157万元，上一交易日主力净流出709万元。该股近5个交易日下跌8.51%，主力资金累计净流出1443万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入1008万元，其中净流入天数为10日。该股主力净额占比0.09%，港股市场排名103/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170408abe9448a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170408abe9448a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","06127","BK1576"],"gpt_icon":0},{"id":"2517899555","title":"金斯瑞生物科技03月05日獲主力加倉250萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517899555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517899555?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:16","pubTimestamp":1741162564,"startTime":"0","endTime":"0","summary":"03月05日, 金斯瑞生物科技股价涨2.09%，报收12.70元，成交金额1.17亿元，换手率0.43%，振幅3.22%，量比0.47。金斯瑞生物科技今日主力资金净流入250万元，连续3日净流入，上一交易日主力净流入599万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为50.00%，平均涨幅为3.63%。该股近5个交易日下跌6.05%，主力资金累计净流出1393万元；近20日主力资金累计净流入7433万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170132a26059c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170132a26059c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","BK1583","HK0000320223.HKD","01548","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD"],"gpt_icon":0},{"id":"2517996620","title":"維亞生物03月05日主力淨流入3萬元 散戶資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517996620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517996620?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 16:15","pubTimestamp":1741162548,"startTime":"0","endTime":"0","summary":"03月05日, 维亚生物股价涨3.91%，报收1.33元，成交金额498万元，换手率0.18%，振幅5.47%，量比0.65。维亚生物今日主力资金净流入3万元，上一交易日主力净流出121万元。该股近5个交易日下跌4.32%，主力资金累计净流出105万元；近20日主力资金累计净流入2034万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305165953abe942ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305165953abe942ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","01873","BK1576"],"gpt_icon":0},{"id":"2517968975","title":"方達控股盤中異動 大幅拉昇5.56%報1.140港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517968975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517968975?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 14:13","pubTimestamp":1741155212,"startTime":"0","endTime":"0","summary":"2025年03月05日下午盘14时13分，方达控股股票出现波动，股价急速拉升5.56%。截至发稿，该股报1.140港元/股，成交量36.8万股，换手率0.02%，振幅4.63%。资金方面，该股资金流入26.134万港元，流出11.874万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。方达控股股票所在的生物技术行业中，整体涨幅为1.44%。该公司的部门包括北美和欧洲以及中国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305141332989cae38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305141332989cae38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","BK1583","01521"],"gpt_icon":0},{"id":"2517495018","title":"港股異動 | 基石藥業-B(02616)漲超8% 治療實體瘤藥物臨牀試驗順利完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2517495018","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517495018?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 14:02","pubTimestamp":1741154541,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B涨超8%，截至发稿，涨8.28%，报3.4港元，成交额1700.51万港元。消息面上，基石药业昨日宣布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。用于治疗多种实体瘤的管线2.0重磅产品CS2009已启动全球多中心临床试验，并率先在澳大利亚递交临床试验申请，未来将陆续扩展至中国及美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","03347","BK1583","BK1161","BK1574","BK1141","BK1576"],"gpt_icon":0},{"id":"2517934765","title":"聯邦制藥現漲超4% 研發的UBT251注射液CKD適應症獲FDA批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517934765","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517934765?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 09:48","pubTimestamp":1741139280,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　联邦制药（03933）盘中涨超5%，截至发稿，股价上涨4.14%，现报13.58港元，成交额2087.91万港元。\n　　消息面上，联邦制药公布，近日，公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局（FDA）许可，同意开展慢性肾脏病（CKD）适应症II期临床试验。此前，CKD适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-05/doc-inenqhut4686473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","03347","BK1141","BK1191","BK1576","03933"],"gpt_icon":0},{"id":"2517461934","title":"港股異動 | 聯邦制藥(03933)漲超5% 研發的UBT251注射液CKD適應症獲FDA批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461934","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517461934?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 09:42","pubTimestamp":1741138931,"startTime":"0","endTime":"0","summary":"消息面上，联邦制药公布，近日，公司全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局许可，同意开展慢性肾脏病适应症II期临床试验。此前，CKD适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。目前，成人2型糖尿病、超重或肥胖、CKD等多个适应症已取得中国及美国两地药物临床试验批准，并已于中国率先进入临床试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","03933","BK1141","BK1191","BK1576","BK1583"],"gpt_icon":0},{"id":"2517202936","title":"復星醫藥(02196.HK)24價肺炎球菌多糖結合疫苗於中國獲批臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517202936","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517202936?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 08:24","pubTimestamp":1741134240,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，旗下控股子公司复星安特金(成都)生物制药，于近日收到国家药监局关于24价肺炎球菌多糖结合疫苗的临床试验批准。复星安特金(成都)生物制药拟于条件具备后于中国境内开展该疫苗的I期临床试验。据介绍，该疫苗为复星医药自主研发的预防用生物制品，拟用于预防由肺炎球菌血清型引起的感染性疾病。截至今年1月，复星医药现阶段针对该疫苗的累计研发投入约为4,400万元人民币。另外，截至周二(4日)，于全球范围内尚无24价肺炎球菌多糖结合疫苗获批上市。(js/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-04 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422161/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0096","BK0028","BK0175","159646","03347","BK1515","BK0012","BK0239","BK1576","BK1141","02196","BK1191","BK1583","BK0187","600196","BK0183","BK0188","BK0196","BK0060","BK1593"],"gpt_icon":0},{"id":"2516603540","title":"泰格醫藥(03347.HK)累計回購980.6萬股A股  總金額5億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2516603540","media":"阿斯达克财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516603540?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 23:27","pubTimestamp":1741102020,"startTime":"0","endTime":"0","summary":"泰格医药(03347.HK) 公布，截至2月28日，累计回购980.63万股A股，约占公司总股本1.1337%；每股作价介乎48.17-62元人民币，成交总金额约5亿人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-04 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210301160531093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210301160531093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422067/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159982","BK0077","03347","BK0028","BK0216","BK0174","BK1141","BK1583","BK1576","LU1820825898.SGD","300347","399300","LU1146622755.USD"],"gpt_icon":0},{"id":"2516672335","title":"泰格醫藥：累計回購公司股份9806300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672335","media":"证券日报网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516672335?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 21:41","pubTimestamp":1741095660,"startTime":"0","endTime":"0","summary":"证券日报网讯3月4日晚间，泰格医药发布公告称，截至2025年2月28日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份9，806，300股，占公司总股本的比例为1.1337%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2025-03-04/doc-inenpfii2571416.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-03-04/doc-inenpfii2571416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0174","BK1141","03347","BK1583","BK1576","LU1146622755.USD","BK0216","BK0028","LU1820825898.SGD","300347","BK0077"],"gpt_icon":0},{"id":"2516678516","title":"中證滬港深創新藥產業指數下跌0.57%，前十大權重包含藥明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2516678516","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516678516?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 20:09","pubTimestamp":1741090175,"startTime":"0","endTime":"0","summary":"金融界3月4日消息，A股三大指数收盘涨跌不一，中证沪港深创新药产业指数 下跌0.57%，报1689.0点，成交额150.83亿元。数据统计显示，中证沪港深创新药产业指数近一个月上涨9.86%，近三个月上涨2.71%，年至今上涨9.18%。从中证沪港深创新药产业指数持仓样本的行业来看，生物药品占比36.25%、化学药占比34.74%、制药与生物科技服务占比25.99%、中药占比1.52%、医疗商业与服务占比1.49%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04200948520078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603259","BK1576","02359","LU1997245177.USD","BK1141","LU2488822045.USD","LU1046422090.SGD","LU2125910500.SGD","LU0320764599.SGD","BK1161","LU0456842615.SGD","LU1997245094.SGD","BK1574","06978","159992","LU0708995583.HKD","LU2242644610.SGD","BK1583","LU2045819591.USD","BK0216","LU0052750758.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":3,"totalSize":219}]}}